Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...
For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice. In this installment, ...
The FDA noted in the letter that it is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD. Outlook Therapeutics, Inc. reported ...
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 ...
The value of attending industry meetings at the beginning of a career in ophthalmology. Attending the American Academy of Ophthalmology (AAO) Annual Meeting for the first time can feel overwhelming.
Panelists discuss how real-world adherence to loading doses and thoughtful switching or reloading strategies can optimize durability and outcomes, particularly in undertreated patients. This segment ...
Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care. This year in retina is almost ...
The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe. The management of retinopathy of prematurity (ROP) ...
Panelists discuss how faricimab and aflibercept 8 mg compare in drying and durability and how clinicians manage IOP considerations tied to injection frequency, volume, and syringe variability. This ...
Lock in patient adherence with discussion of study results. A recent Modern Retina Case-Based Roundtable focused on strategies to protect vision in patients with geographic atrophy (GA), according to ...
Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases. This ...
This approach helps distinguish diseases associated with macular atrophy. The numbers are small, they noted, but an incorrect diagnosis can lead to inappropriate treatment. In their conclusion, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback